2023 World Conference on Lung Cancer (Posters)-P2.05. Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort

P2.05. Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the association between immune-related adverse events (irAEs) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors (ICPi). The study used data from the Alberta Immunotherapy Database (AID), a provincial multi-center observational cohort. The primary endpoint was the association between irAEs and OS, and only clinically impactful irAEs were included in the analysis.<br /><br />A total of 803 patients treated with ICPi were included in the study, and 297 (37%) of them experienced an irAE. The most common irAEs were pneumonitis, dermatitis, and colitis. Patients with certain prognostic characteristics, such as age <60, ECOG 0, high PDL-1 expression, no bone metastases, and normal hemoglobin, albumin, and LDH levels, were more likely to develop irAEs. Gender, histology, driver mutation, treatment line, and type of ICPi were not associated with the development of irAEs.<br /><br />When immortal time bias was mitigated, patients with confirmed irAEs had longer OS and longer time to next treatment compared to those without irAEs. The incidence of irAEs remained independently associated with OS after adjusting for known prognostic characteristics. The study also found that the setting of irAE treatment (inpatient vs. outpatient) did not affect OS.<br /><br />In conclusion, this study provides the largest real-world dataset to date on the association between clinically impactful irAEs and survival in metastatic NSCLC. Patients with certain prognostic characteristics were more likely to develop irAEs, and those who developed irAEs had significantly longer survival when immortal time bias was considered. This highlights the importance of monitoring and managing irAEs in patients receiving ICPi for metastatic NSCLC.

Asset Subtitle

Sarah Cook

Meta Tag

Speaker Sarah Cook

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

immune-related adverse events

overall survival

metastatic non-small cell lung cancer

immune-checkpoint inhibitors

Alberta Immunotherapy Database

observational cohort

pneumonitis

dermatitis

colitis

prognostic characteristics